Thulasi Praneetha, Djalilian Ali Reza
Department of Ophthalmology, Emory University, Atlanta, Georgia.
Department of Ophthalmology & Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois.
Ophthalmology. 2017 Nov;124(11S):S27-S33. doi: 10.1016/j.ophtha.2017.07.022.
Dry eye disease (DED) represents a heterogeneous group of conditions with tear film insufficiency and signs and/or symptoms of ocular surface irritation. The clinical manifestations of DED can be highly variable; hence the diagnosis is often based on a combination of symptoms, signs, and clinical tests, given that any one of these alone would miss a significant number of patients. Similarly, the treatment must often be tailored to each patient by targeting the specific mechanisms involved in his or her disease. The purpose of this review is to summarize recent advances that have allowed us to better recognize, categorize, and treat patients with DED. The most notable new diagnostic tests in DED are tear film osmolarity, inflammatory biomarkers, and meibomian gland imaging. Therapeutically, anti-inflammatory therapy, meibomian gland heating and expression, and scleral contact lenses are some of the latest options available for treating DED.
干眼疾病(DED)是一组异质性病症,伴有泪膜不足以及眼表刺激的体征和/或症状。DED的临床表现差异很大;因此,鉴于仅依据这些因素中的任何一项都会遗漏大量患者,其诊断通常基于症状、体征和临床检查的综合判断。同样,治疗通常必须针对每位患者所患疾病涉及的具体机制进行个性化定制。本综述的目的是总结近期取得的进展,这些进展使我们能够更好地识别、分类和治疗DED患者。DED中最显著的新型诊断检查是泪膜渗透压、炎症生物标志物和睑板腺成像。在治疗方面,抗炎治疗、睑板腺热敷和挤压以及巩膜接触镜是目前可用于治疗DED的一些最新选择。